NCT04903652View on ClinicalTrials.gov

Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

February 1, 2022

Study Completion Date

February 6, 2022

Conditions
HER2-positive Advanced Breast Cancer
Interventions
DRUG

Pyrotinib Maleate

Pyrotinib p.o. 400 mg once daily

DRUG

Vinorelbine

Vinorelbine p.o. 40 mg once every other day

Trial Locations (1)

Unknown

Tianjin Cancer Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT04903652 - Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer | Biotech Hunter | Biotech Hunter